

## Corrigendum

**Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials****Mark C. Genovese<sup>1</sup>, Eduardo Mysler<sup>2</sup>, Tetsuya Tomita<sup>3</sup>, Kim A. Papp<sup>4</sup>, Carlo Salvarani<sup>5</sup>, Sergio Schwartzman<sup>6</sup>, Gaia Gallo<sup>7</sup>, Himanshu Patel<sup>7</sup>, Jeffrey R. Lisse<sup>7</sup>, Andris Kronbergs<sup>7</sup>, Soyi Liu Leage<sup>7</sup>, David H. Adams<sup>7</sup>, Wen Xu<sup>7</sup>, Helena Marzo-Ortega<sup>8</sup> and Mark G. Lebwohl<sup>9</sup>**Rheumatology 2020;59:38353845  
doi: 10.1093/rheumatology/keaa189

In the originally published version of this manuscript, there were errors in the rate of latent TB reported for IXE PsA population. These errors have been corrected online.

Specifically, the following changes have been made:

The definition of latent tuberculosis in the methods section has been corrected to: 'Latent tuberculosis (TB) infection was based by either latent tuberculosis or a positive result on any of the following annual tests: tuberculin skin test, interferon-gamma release assay, or mycobacterium tuberculosis complex test.'

Discontinuation in the PsA population in the results section has been corrected to: 'The main causes of discontinuation in the PsA population were latent TB (either latent tuberculosis or a positive result on any of the following annual tests: tuberculin skin test, interferon-gamma release assay, or mycobacterium tuberculosis complex test; n = 20, IR = 0.8 per 100 PY), ISR (n = 5, IR 0.2 per 100 PY) and pneumonia (n = 3, IR 0.1 per 100 PY).'

Table 3, line 'Latent tuberculosis infections', column 'Pooled PsA IXE' has been corrected to: n (%) 35(2.5), IR 1.6, and 95% CI 1.1, 2.2.

Table 3, footnote 'a' has been corrected to: 'Includes either latent tuberculosis or a positive result on any of the following annual tests: tuberculin skin test, interferon-gamma release assay, or mycobacterium tuberculosis complex test.'

A sentence in the results section has been corrected to: 'Latent TB infection was reported by 105 patients with PsO (IR 0.6 per 100 PY), 35 patients with PsA (IR 1.6 per 100 PY), and 1 patient with axSpA (IR 0.1 per 100 PY).'

A sentence in the discussion section has been corrected to: 'Overall, annual TB testing revealed 141 patients across populations (PsO n = 105, PsA n = 35, axSpA n = 1) with latent TB infections.'

The following sentence has been removed from the discussion section: 'No cases of positive TB seroconversion were reported in the axSpA population.'

And another sentence in the discussion section has been corrected to: 'Positive TB tests led to discontinuation (which was protocol-specified for a portion of the studies) for 67 patients with PsO and 20 patients with PsA. However, no confirmed cases of TB reactivation occurred in the ixekizumab clinical trials, including patients with latent or previously treated Mycobacterium tuberculosis infection.'

<sup>1</sup>Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA, <sup>2</sup>Organización Médica de Investigación, Buenos Aires, Argentina, <sup>3</sup>Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, <sup>4</sup>Clinical Research and Probiotic Medical Research Inc., Waterloo, and the University of Toronto, Toronto, Canada, <sup>5</sup>Azienda USL-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Modena, Emilia-Romagna, Italy, <sup>6</sup>Department of Medicine, The Hospital for

Special Surgery, New York, NY, <sup>7</sup>Eli Lilly and Company, Indianapolis, IN, USA, <sup>8</sup>NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, UK and <sup>9</sup>Department of Dermatology, Mount Sinai Hospital, New York, NY, USA  
Correspondence to: Mark C. Genovese, Department of Medicine, Stanford University Medical Center, 1000 Welch Road, Suite 202, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu